Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate.
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D002087:Butyrates / Q000008:administration & dosage* / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000008:administration & dosage* / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008875:Middle Aged; D009539:Nicotinic Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D010647:Phenyl Ethers / Q000008:administration & dosage / Q000627:therapeutic use; D011409:Propylene Glycols / Q000008:administration & dosage* / Q000627:therapeutic use; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
D000924:Anticholesteremic Agents; D002087:Butyrates; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D009539:Nicotinic Acids; D010647:Phenyl Ethers; D011409:Propylene Glycols; D014280:Triglycerides; D014527:Uric Acid; D002784:Cholesterol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D002994:Clofibrate